Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma: A Multi-center, Open-label, Prospective Clinical Study

NCT04716686 is registered in ClinicalTrials.gov with Shandong University as lead sponsor.

NCT NCT04716686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04716686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma: A Multi-center, Open-label, Prospective Clinical Study
Lead sponsor
Shandong University
Phase
Phase 2
Overall status
Recruiting
Start date
June 1, 2021
Completion date
December 31, 2026
Enrollment
83 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial carcinoma, serous carcinoma